Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
Enzolytics, Inc. (OTC PINK:ENZC) announced positive results from a study conducted at the National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria. The study concluded that the company's patented experimental cancer lyophilized pepsin treatment effectively reduces the growth and spread of cancer cells in various types of cancer, including breast, colon, prostate, larynx, and small cell lung cancer.
The report, authored by Associate Professor Petya Genova-Kalu and Professor Dr. Iva Hristova, states that the polypeptide complex of lyophilized pepsin causes cytopathological changes and significantly reduces the survival and proliferative activity of cancer cell cultures. The effect was observed to be time- and concentration-dependent. The scientists concluded that lyophilized pepsin has extremely promising biomedical potential.
Enzolytics, Inc. (OTC PINK:ENZC) ha annunciato risultati positivi da uno studio condotto al Centro Nazionale di Malattie Infettive e Parassitarie di Sofia, Bulgaria. Lo studio ha concluso che il trattamento sperimentale con pepsina liofilizzata brevettata dell'azienda riduce efficacemente la crescita e la diffusione delle cellule tumorali in diversi tipi di cancro, inclusi cancro al seno, al colon, alla prostata, della laringe e del polmone a piccole cellule.
Il rapporto, redatto dalla Professoressa Associata Petya Genova-Kalu e dal Professor Dr. Iva Hristova, afferma che il complesso di polipeptidi di pepsina liofilizzata provoca cambiamenti citopatologici e riduce significativamente la sopravvivenza e l'attività proliferativa delle colture cellulari tumorali. L'effetto è stato osservato essere dipendente dal tempo e dalla concentrazione. Gli scienziati hanno concluso che la pepsina liofilizzata ha un potenziale biomedico estremamente promettente.
Enzolytics, Inc. (OTC PINK:ENZC) anunció resultados positivos de un estudio realizado en el Centro Nacional de Enfermedades Infecciosas y Parasitarias en Sofía, Bulgaria. El estudio concluyó que el tratamiento experimental de pepsina liofilizada patentada de la empresa reduce efectivamente el crecimiento y la propagación de células cancerosas en varios tipos de cáncer, incluidos cáncer de mama, de colon, de próstata, de laringe y cáncer de pulmón de células pequeñas.
El informe, elaborado por la Profesora Asociada Petya Genova-Kalu y el Profesor Dr. Iva Hristova, indica que el complejo de polipéptidos de pepsina liofilizada provoca cambios citopatológicos y reduce significativamente la supervivencia y la actividad proliferativa de las culturas de células cancerosas. Se observó que el efecto era dependiente del tiempo y de la concentración. Los científicos concluyeron que la pepsina liofilizada tiene un potencial biomédico extremadamente prometedor.
Enzolytics, Inc. (OTC PINK:ENZC)는 불가리아 소피아에 있는 국가 감염 및 기생질병 센터에서 실시된 연구에서 긍정적인 결과를 발표했습니다. 이 연구는 회사의 특허를 받은 실험적 암 리오필라이즈드 펩신 치료법이 유방, 대장, 전립선, 후두 및 소세포 폐암을 포함한 다양한 암의 세포 성장과 확산을 효과적으로 줄인다고 결론지었습니다.
피타 제노바-카루 조교수와 이바 흐리스토바 교수의 저서인 이 보고서는 리오필라이즈드 펩신의 폴리펩타이드 복합체가 세포병리학적 변화를 유발하며 암 세포 배양의 생존율과 증식 활성을 유의미하게 줄인다고 밝혔습니다. 그 효과는 시간과 농도에 따라 달라지는 것으로 관찰되었습니다. 과학자들은 리오필라이즈드 펩신이 매우 유망한 생의학적 잠재력을 가지고 있다고 결론지었습니다.
Enzolytics, Inc. (OTC PINK:ENZC) a annoncé des résultats positifs d'une étude réalisée au Centre National des Maladies Infectieuses et Parasitaires à Sofia, en Bulgarie. L'étude a conclu que le traitement expérimental à base de pepsine liofilisée brevetée de l'entreprise réduit efficacement la croissance et la propagation des cellules cancéreuses dans divers types de cancer, y compris cancer du sein, cancer colorectal, cancer de la prostate, cancer du larynx et cancer du poumon à petites cellules.
Le rapport, rédigé par la professeure associée Petya Genova-Kalu et le professeur Dr. Iva Hristova, indique que le complexe de polypeptides de pepsine liofilisée entraîne des changements cytopathologiques et réduit significativement la survie et l'activité proliférative des cultures cellulaires cancéreuses. L'effet a été observé comme étant dépendant du temps et de la concentration. Les scientifiques ont conclu que la pepsine liofilisée possède un potentiel biomédical extrêmement prometteur.
Enzolytics, Inc. (OTC PINK:ENZC) gab positive Ergebnisse aus einer Studie bekannt, die am Nationalen Zentrum für Infektions- und Parasitärerkrankungen in Sofia, Bulgarien durchgeführt wurde. Die Studie kam zu dem Schluss, dass die patentierte experimentelle Krebs-Lyophilisierte Pepsintherapie des Unternehmens das Wachstum und die Ausbreitung von Krebszellen bei verschiedenen Krebsarten, einschließlich Brust-, Dickdarm-, Prostata-, Kehlkopf- und kleinzelligem Lungenkrebs, effektiv reduziert.
Der Bericht, verfasst von der außerordentlichen Professorin Petya Genova-Kalu und Professor Dr. Iva Hristova, besagt, dass der Polypeptidkomplex der lyophilisierten Pepsin zytopathologische Veränderungen verursacht und die Überlebens- und Proliferationsaktivität von Krebszellkulturen signifikant reduziert. Der Effekt war zeit- und konzentrationsabhängig. Die Wissenschaftler kamen zu dem Schluss, dass die lyophilisierte Pepsin äußerst vielversprechendes biomedizinisches Potenzial hat.
- Study concludes Enzolytics' patented cancer treatment is effective in reducing growth and spread of multiple cancer types
- Treatment shows strongest effect on mammary adenocarcinoma, cervical carcinoma, colorectal carcinoma, and prostate adenocarcinoma
- Scientists describe the lyophilized pepsin as having 'extremely promising biomedical potential'
- None.
ALLEN, TX / ACCESSWIRE / August 20, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that a study conducted at the Ministry of Health National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria concluded that inventor Harry Zhabilov's patented experimental cancer lyophilized pepsin treatment, exclusively licensed to Enzolytics, is effective in decreasing the growth and spread of cancer cells in breast cancer, colon cancer, prostate cancer, cancer of the larynx, as well as small cell lung cancer.
The Conclusion of the report by Associate Professor Petya Genova-Kalu and Professor Dr. Iva Hristova, in its entirety reads as follows:
"A polypeptide complex of lyophilized pepsin, causes cytopathological changes and significantly reduces the survival and/or proliferative activity of the cell cultures used as experimental models. The tested substance exhibits the strongest cytotoxic/cytostatic effect on mammary adenocarcinoma (MCF-7 and MDA-MB-231 lines), cervical carcinoma (HeLa line), colorectal carcinoma (CaCo-2 line) and adenocarcinoma of the prostate (PC-3). A cytotoxic/cytostatic effect was observed on cells from small cell lung cancer (A 549 line) and the line Hep-2 (carcinoma of the larynx). The observed effect was time- and concentration-dependent a response that is most likely due to the different biological characteristics of the malignant neoplasms from which the model cell lines were derived, as well as to the phenomenon of heterogeneity of tumor cells.
In conclusion, lyophilized pepsin has extremely promising biomedical potential."
Inventor and Chief Science Officer of Enzolytics, Harry Zhabilov says, "I have always believed in my product and I am so glad that such distinguished scientists as Prof. Genova-Kalu and Prof. Dr. Iva Hristova have been able to validate our findings." The study was commissioned by Rosetta Lifecare BG AD working in conjunction with the Company.
President and CEO of Enzolytics, Steve Sharabura says, "We are all here because we believe in Harry Zhabilov's science and are thrilled this report came back with such amazing results. We look forward to working towards getting this product approved."
About Enzolytics, Inc.
Enzolytics, Inc. is transitioning from a drug development company committed to commercializing its licensed proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted areas of sales, marketing and distribution of medical devices, medical testing and nutraceutical products.
Forward Looking Statements
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company's ability to enter into a definitive business combination agreement and Company's ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company's stockholders and the amount of funds remaining in Company's trust account after satisfaction of such requests; those factors discussed in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading "Risk Factors," and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company's expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company's assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company's assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
CONTACT INFORMATION:
Enzolytics, Inc.
Steve Sharabura, Chief Executive Officer
3002 Royal Palm
Baytown, Texas 77523
Tel: (845) 925-4597
X/Twitter: @EnzolyticsInc
SOURCE: Enzolytics, Inc.
View the original press release on accesswire.com
FAQ
What types of cancer did Enzolytics' (ENZC) lyophilized pepsin treatment show effectiveness against?
Who conducted the study on Enzolytics' (ENZC) cancer treatment?
What were the main findings of the study on Enzolytics' (ENZC) lyophilized pepsin treatment?
When was the study on Enzolytics' (ENZC) cancer treatment announced?
